Interleukin Genetics Inc., of Waltham, Mass., has agreed to provide genetic testing services for Carlsbad, Calif.-based Isis Pharmaceuticals Inc.'s phase II study of ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.